Etiket: Therapeutics
GNW-Adhoc: ADC Therapeutics announces acceptance of abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting
^Preclinical data support future clinical development of AWK, that target Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies to evaluate ADCT-601 targeting AXL LAUSANNE, Switzerland, March 07,…
GNW-Adhoc: ADC Therapeutics participates in the Guggenheim 5th Annual Healthy Altitudes Summit
^LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will take part in a Fireside chat at the…
GNW-Adhoc: ADC Therapeutics again meets the standards for continued listing on the NYSE
^LAUSANNE, Switzerland, Jan. 05, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) announced today that the Company will be acquired by the New York Stock Exchange on January 2,…
GNW-Adhoc: ALSA Ventures founds new gene therapy portfolio company Axovia Therapeutics to treat ciliopathies
^* Development of the first gene therapy to treat diseases caused by a dysfunction of the cilia can be caused * AXV101 targets retinal dystrophy in patients with Bardet-Biedl syndrome…
ADC Therapeutics announces updated results from the LOTIS-2 study to be presented at the 2023 European Hematology Association Hybrid Congress
shares in this article ADC Therapeutics SA (NYSE: ADCT) today announced that updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab-tesirin-Lpyl) in patients with relapsed/refractory diffuse…
ADC Therapeutics Attends Morgan Stanley 20th Annual Global Healthcare Conference
shares in this article ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global…
ADC Therapeutics announces results from a pivotal Phase II clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin’s lymphoma
shares in this article ADC Therapeutics SA (NYSE: ADCT) today announced results from its ongoing pivotal Phase II clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory…
ADC Therapeutics Announces Abstract Presentation at the 2022 European Hematology Association (EHA) Hybrid Congress
shares in this article ADC Therapeutics SA (NYSE: ADCT) today announced that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory…
Outlook: Cara Therapeutics gives investors a look at the books
shares in this article At the financial conference taking place on May 9th, 2022, Cara Therapeutics will present the figures for the most recent quarter, which ended on March 31st,…